E-resources
Peer reviewed
Open access
-
Passeri, Thibault; Dahmani, Ahmed; Masliah-Planchon, Julien; El Botty, Rania; Courtois, Laura; Vacher, Sophie; Marangoni, Elisabetta; Nemati, Fariba; Roman-Roman, Sergio; Adle-Biassette, Homa; Mammar, Hamid; Froelich, Sébastien; Bièche, Ivan; Decaudin, Didier
Frontiers in oncology, 11/2022, Volume: 12Journal Article
Management of advanced chordomas remains delicate considering their insensitivity to chemotherapy. Homozygous deletion of the regulatory gene has been described as the most frequent genetic alteration in chordomas and may be considered as a potential theranostic marker. Here, we evaluated the tumor efficacy of the CDK4/6 inhibitor palbociclib, as well as the PLK1 inhibitor volasertib, in three chordoma patient-derived xenograft (PDX) models to validate and identify novel therapeutic approaches. From our chordoma xenograft panel, we selected three models, two of them harboring a homozygous deletion of genes, and the last one a pathogenic variant (as control). For each model, we tested the palbociclib and volasertib drugs with pharmacodynamic studies together with RT-PCR and RNAseq analyses. For palbociclib, we observed a significant tumor response for one of two models harboring the deletion of (p = 0.02), and no significant tumor response in the -mutated PDX; for volasertib, we did not observe any response in the three tested models. RT-PCR and RNAseq analyses showed a correlation between cell cycle markers and responses to palbociclib; finally, RNAseq analyses showed a natural enrichment of the oxidative phosphorylation genes (OxPhos) in the palbociclib-resistant PDX (p = 0.02). CDK4/6 inhibition appears as a promising strategy to manage advanced chordomas harboring a loss of . However, further preclinical studies are strongly requested to confirm it and to understand acquired or resistance to palbociclib, in the peculiar view of a targeting of the oxidative phosphorylation genes.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.